APOE and Alzheimer disease: Furthermore, diminished Cerebral Glucose Metabolism is proposed as a useful marker to predict AD, especially in APOE4 carriers, many years before cognitive impairment is confirmed, and taking into consideration research on DCGM in T2D is suggested, since this would be a unique test for T3D development.